Q-VANT is a privately held company that has solved the supply chain problem of QS-21 and other Quillaja-based saponin adjuvants for the global human and animal pharmaceutical markets.  The company’s next-generation technology platform combines computational learning techniques with a proprietary multi-step purification process to increase the supply of QS-21 by more than 1,000 – enabling the production of billions of doses annually to meet today’s increasing global market demand. Led by a team with unrivalled experience in vaccine and adjuvant development, manufacturing and global regulatory requirements, and with world-class knowledge in Quillaja saponin supply chain, agronomy, extraction and purification, Q-VANT is the first company that is vertically integrated to combine a secured sustainable Quillaja raw material supply with pharma cGMP commercial-scale production of QS-21 and other saponin-based adjuvants. For more information, visit www.q-vant.com.

Biotechnology

Logistics & Supply Chain

Pharmaceutical

Q-VANT Biosciences

Q-VANT Biosciences' headquarters in Forestdale, United States

Description

People (1)

Douglas Klaiber

Jobs